Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.38 |
| ▸ | NPC1 | O15118 | 4/20 | 0.38 |
| ▸ | RAB9A | P51151 | 4/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.38 |
| ▸ | RELA | Q04206 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.35 |
| ▸ | CASP3 | P42574 | 1/20 | 0.35 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.35 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.35 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1857233 | 1.00 | MAPT (0.38) | MAPTALDH1A1NPC1RAB9ANFKB1 | |
| SCHEMBL2688156 | 1.00 | MAPT (0.38) | MAPTALDH1A1NPC1RAB9ANFKB1 | |
| SCHEMBL18590268 | 0.83 | NPC1 (0.36) | MAPTALDH1A1NPC1RAB9ANFKB1 | |
| SCHEMBL18590271 | 0.83 | KCNH2 (0.37) | MAPTALDH1A1NPC1RAB9ANFKB1 | |
| SCHEMBL18590317 | 0.80 | HTT (0.33) | MAPTALDH1A1NPC1RAB9ANFKB1 | |
| SCHEMBL2687783 | 0.79 | HTT (0.59) | MAPTALDH1A1NPC1RAB9ANFKB1 | |
| SCHEMBL2687788 | 0.79 | HTT (0.59) | MAPTALDH1A1NPC1RAB9ANFKB1 | |
| SCHEMBL2687786 | 0.79 | HTT (0.59) | MAPTALDH1A1NPC1RAB9ANFKB1 | |
| SCHEMBL13606738 | 0.79 | MAPT (0.47) | MAPTALDH1A1NPC1RAB9ANFKB1 | |
| SCHEMBL18590259 | 0.79 | HTT (0.35) | MAPTALDH1A1NPC1RAB9ANFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9988361-B2 | Anti-enterovirus 71 thiadiazolidine derivative | JIANGSU KANION PHARMACEUTICAL CO., LTD. (CN) | 2018-06-05 | — | — | US | disclosed |
| US-9988361-B2 | Anti-enterovirus 71 thiadiazolidine derivative | JIANGSU KANION PHARMACEUTICAL CO., LTD. (CN) | 2018-06-05 | — | — | US | disclosed |
| US-20170066732-A1 | ANTI-ENTEROVIRUS 71 THIADIAZOLIDINE DERIVATIVE | Jiangsu Kanion pharmaceutical CO. LTD (CN) | 2017-03-09 | — | — | US | disclosed |
| US-20170066732-A1 | ANTI-ENTEROVIRUS 71 THIADIAZOLIDINE DERIVATIVE | Jiangsu Kanion pharmaceutical CO. LTD (CN) | 2017-03-09 | — | — | US | disclosed |
| US-8487116-B2 | Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBVIE INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-20120277190-A1 | PRODRUGS OF COMPOUNDS THAT INHIBIT TRPV1 RECEPTOR | ABBVIE INC. | 2012-11-01 | — | — | US | disclosed |
| US-8232309-B2 | Prodrugs of compounds that inhibit TRPV1 receptor | ABBOTT LABORATORIES (US) | 2012-07-31 | — | — | US | disclosed |
| US-20120190845-A1 | FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ABBVIE INC. | 2012-07-26 | — | — | US | disclosed |
| US-8071762-B2 | Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBOTT LABORATORIES (US) | 2011-12-06 | — | — | US | disclosed |
| US-8026256-B2 | Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor | ABBOTT LABORATORIES (US) | 2011-09-27 | — | — | US | disclosed |
| EP-1957464-A1 | INDAZOLE DERIVATIVES THAT INHIBIT TRPVl RECEPTOR | Abbott Laboratories (US) | 2008-08-20 | — | — | EP | disclosed |
| US-7375126-B2 | Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBOTT LABORATORIES (US) | 2008-05-20 | — | — | US | disclosed |
| WO-2007050732-A1 | INDAZOLE DERIVATIVES THAT INHIBIT TRPVl RECEPTOR | ABBOTT LABORATORIES (US) | 2007-05-03 | — | — | WO | disclosed |
| US-20070099954-A1 | Prodrugs of compounds that inhibit TRPV1 receptor | ABBVIE INC. | 2007-05-03 | — | — | US | disclosed |
| EP-1658269-A1 | FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | Abbott Laboratories (US) | 2006-05-24 | — | — | EP | disclosed |
| US-7015233-B2 | Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor | ABBOTT LABORATORIES (US) | 2006-03-21 | — | — | US | disclosed |
| US-20060035934-A1 | Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor | ABBVIE INC. | 2006-02-16 | — | — | US | disclosed |
| US-20050043351-A1 | Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBVIE INC. | 2005-02-24 | — | — | US | disclosed |
| WO-2004111009-A1 | FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ABBOTT LABORATORIES (US) | 2004-12-23 | — | — | WO | disclosed |
| US-20040254188-A1 | Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBVIE INC. | 2004-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277190-A1 | PRODRUGS OF COMPOUNDS THAT INHIBIT TRPV1 RECEPTOR | TRPV1, TRPV3, TRPA1 | MAPT 2250/4885ALDH1A1 583/4885NPC1 2255/4885 |
| US-20060035934-A1 | Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor | TRPV1, TRPV2, OPRL1 | MAPT 2857/4885ALDH1A1 385/4885NPC1 3856/4885 |
| US-20170066732-A1 | ANTI-ENTEROVIRUS 71 THIADIAZOLIDINE DERIVATIVE | EIF2AK2, GTF3C5, GTF3C1 | MAPT 3673/4885ALDH1A1 1424/4885NPC1 1136/4885 |
| US-20040254188-A1 | Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | TRPV1, OPRL1, TRPV2 | MAPT 2937/4885ALDH1A1 305/4885NPC1 3785/4885 |
| US-20050043351-A1 | Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ARRB1, TRPV1, TRPV5 | MAPT 4737/4885ALDH1A1 1865/4885NPC1 871/4885 |
| US-20070099954-A1 | Prodrugs of compounds that inhibit TRPV1 receptor | TRPV1, TRPV3, TRPA1 | MAPT 2250/4885ALDH1A1 583/4885NPC1 2255/4885 |
| US-20120190845-A1 | FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ARRB1, TRPV1, TRPV5 | MAPT 4755/4885ALDH1A1 1901/4885NPC1 942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.